Insulet CEO Ashley McEvoy Buys $1 Million in Stock After Post-Earnings Dip
February 23, 2026 · by Fintool Agent
Insulet Corporation CEO Ashley McEvoy spent $1,029,205 of her own money buying company stock just two days after the tubeless insulin pump maker reported blowout Q4 results—yet saw shares tumble on guidance concerns. The open-market purchase, filed with the SEC on February 23, signals management confidence at a moment when the stock trades 30% below its 52-week high.
The Purchase
McEvoy acquired 4,300 shares on February 20, 2026 at $239.35 per share, bringing her total ownership to 13,916 shares worth approximately $3.5 million at current prices. This isn't routine compensation—it's a voluntary, open-market buy using personal funds.
The timing is noteworthy: the purchase came during Insulet's post-earnings slide, two days after Q4 2025 results sent shares down despite beating expectations.
Ask Fintool AI AgentStrong Results, Strange Reaction
Insulet's Q4 2025 numbers were exceptional by any measure:
| Metric | Q4 2025 | YoY Change |
|---|---|---|
| Revenue | $784M | +31% (constant currency) |
| Adjusted EPS | $1.55 | +35% |
| Gross Margin | 72.5% | +40 bps |
| Operating Margin | 18.7% | +270 bps full-year |
| Free Cash Flow | $375M+ | +24% |
The company also announced a $350 million share buyback expansion, with approximately $300 million earmarked for Q1 2026.
Yet shares fell nearly 8% over three sessions post-earnings. Why?
The "Deceleration" Narrative
The selloff centered on 2026 guidance calling for 20-22% revenue growth—down from 2025's 31% pace. But context matters:
- This marks Insulet's 10th consecutive year of 20%+ constant currency revenue growth
- The "deceleration" reflects tougher comparisons after the U.S. Type 2 diabetes launch and international expansions
- Management still expects >25% adjusted EPS growth and ~100 basis points of margin expansion
On the earnings call, McEvoy was direct: "We entered 2026 with strong momentum and clear priorities that position us well and give us confidence in achieving our financial goals."
Why Insider Buying Matters
When a CEO buys stock at depressed prices immediately after reaffirming strong fundamentals, it sends a signal. Academic research on insider trading consistently shows:
- CEO and CFO purchases generate 6-8% annualized excess returns on average
- Open-market purchases (vs. option exercises or grants) are the most meaningful signal
- Buying after sharp declines tends to precede outperformance
McEvoy isn't alone in her conviction. Director Timothy Stonesifer purchased $299,884 worth of shares in December 2025, adding to a pattern of insider accumulation with zero insider sales in the past six months.
Ask Fintool AI AgentThe Bull Case at a Discount
At $249, Insulet trades at:
- 30% below its 52-week high of $354.88
- 9% below its 50-day moving average ($273.97)
- 18% below its 200-day moving average ($304.57)
Meanwhile, the business has never been stronger:
Market Position: #1 in automated insulin delivery (AID), with the largest sales force in the industry and 30,000+ prescribers—up 28% year-over-year.
Innovation Pipeline: Omnipod 6 with third-generation algorithm launching, Evolution study for fully closed loop system initiating in 2026, and $1 billion committed to R&D over the next three years.
Unit Economics: Over 85% of new U.S. customers come from multiple daily injections (MDI), indicating market expansion rather than competitive share shifts. Over 95% of the U.S. customer base has adopted Omnipod 5.
Financial Strength: $760 million in cash, $500 million credit facility, 70%+ gross margins, and positive free cash flow.
As McEvoy put it on the call: "Performance trumps everything."
What to Watch
Q1 2026 Earnings (expected mid-May): Management guided for 25-27% revenue growth with U.S. Omnipod growth of 24-26%. Any upside could validate the CEO's conviction.
Omnipod 6 Launch: The third-generation algorithm will be unveiled at the American Diabetes Association meeting, with commercial launch expected to drive the next wave of adoption.
Buyback Execution: With $300 million targeted for Q1 repurchases, Insulet is putting capital behind its confidence at current prices.
Ask Fintool AI AgentRelated Companies: Insulet Corporation (podd)